Bone Fragility in Type 2 Diabetes Mellitus

Type 2 diabetes mellitus (T2DM) is increasingly recognised as a condition that paradoxically preserves or even elevates bone mineral density yet confers a markedly increased risk of fragility fractures. Patients with T2DM often display normal dual-energy X-ray absorptiometry readings, but their bone quality is compromised by a constellation of metabolic and microvascular disturbances. Chronic hyperglycaemia promotes the formation of advanced glycation end-products within collagen matrices, impairing the material properties of bone and reducing toughness. Concomitant alterations in bone remodelling—driven by insulin resistance, low bone turnover and perturbed osteoblast and osteoclast function—further undermine structural integrity. Microvascular damage and diabetic neuropathy also contribute to fall risk, compounding skeletal fragility. Conventional fracture risk assessments and generalised screening tools tend to underestimate fracture propensity in people with T2DM, highlighting the need for diabetes-specific paradigms that integrate metabolic, genetic and biomechanical factors. Addressing skeletal health in T2DM requires multifaceted strategies: tightening glycaemic control to limit glycation, optimising muscle function and fall prevention, and selecting antidiabetic therapies that do not exacerbate bone loss or hypoglycaemic episodes. Emerging biomarkers and imaging techniques promise refined risk stratification, while translational research continues to unravel the complex interplay between glucose metabolism and bone homeostasis.

Research from Nature Portfolio

A large propensity-matched cohort analysis assessed the impact of insulin initiation on fracture incidence in early T2DM. Compared with matched non-users, patients commencing insulin experienced a 38% relative increase in major fragility fractures, suggesting that the hypoglycaemic fluctuations or direct effects of insulin in early disease stages may heighten skeletal vulnerability. These findings underscore the importance of incorporating fracture risk assessment into decisions about insulin therapy and tailoring preventive measures around treatment initiation.

Bone Fragility in Type 2 Diabetes Mellitus publication trend

The graph below shows the total number of articles in bone fragility in type 2 diabetes mellitus across all publications each year (not limited to Nature Index journals).

Technical terms

Bone mineral density (BMD): Quantitative measure of mineral content in bone, expressed in grams per square centimetre and used to assess fracture risk.

Bone turnover markers: Biochemical indicators of bone formation and resorption, such as P1NP and CTX, reflecting remodelling dynamics.

Advanced glycation end-products (AGEs): Irreversible protein cross-links formed in hyperglycaemia that stiffen collagen and diminish bone toughness.

Trabecular microarchitecture: Three-dimensional structure of spongy bone, critical for load distribution and impact resistance.

Osteoblasts and osteoclasts: Specialized cells responsible, respectively, for new bone formation and old bone resorption in the remodelling cycle.

References

1. Deciphering the complex relationship between type 2 diabetes and fracture risk with both genetic and observational evidence. eLife (2024).
2. Bone metabolism in diabetes: a clinician’s guide to understanding the bone–glucose interplay. Diabetologia (2024).
3. Risk of fracture in adults with type 2 diabetes in Sweden: A national cohort study. PLOS Medicine (2023).
4. Insulin use and Excess Fracture Risk in Patients with Type 2 Diabetes: A Propensity-Matched cohort analysis. Scientific Reports (2017).